Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models

European Journal of Pharmacology

Volumn 700, Issue 1-3, 2013, Pages 93-101

  Wagner, Karen ^a   Inceoglu, Bora ^a   Dong, Hua ^a   Yang, Jun ^a   Hwang, Sung Hee ^a   Jones, Paul ^a   Morisseau, Christophe ^a   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetic neuropathic pain; Epoxygenated fatty acid; Inflammatory pain; Nociception; Soluble epoxide hydrolase

Indexed keywords

1 (1 ACETYPIPERIDIN 4 YL) 3 ADAMANTANYLUREA; 4 [4 (3 TRIFLUOROMETHOXYPHENYL YL UREIDO)CYCLOHEXYLOXY]BENZOIC ACID; 4 [4 [3 (1 ADAMANTYL)UREIDO]CYCLOHEXYLOXY]BENZOIC ACID; ANALGESIC AGENT; CELECOXIB; EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; LIPOPOLYSACCHARIDE; MORPHINE; OXYLIPIN; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE CONTROL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG STRUCTURE; ENZYME INHIBITION; INFLAMMATORY PAIN; LOW DRUG DOSE; MALE; NEUROPATHIC PAIN; NONHUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; ENZYME INHIBITORS; EPOXIDE HYDROLASES; INFLAMMATION; NEURALGIA; OXYLIPINS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TIME FACTORS;

EID: 84872512484     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.12.015     Document Type: Article

References (38)

1. K.O. Aley, and J.D. Levine Rapid onset pain induced by intravenous streptozotocin in the rat J. Pain 2 2001 146 150 (Pubitemid 32550236)
2. S.-K. Anandan, H.K. Webb, D. Chen, Y.-X. Wang, B.R. Aavula, S. Cases, Y. Cheng, Z.N. Do, U. Mehra, V. Tran, J. Vincelette, J. Waszczuk, K. White, K.R. Wong, L.-N. Zhang, P.D. Jones, B.D. Hammock, D.V. Patel, R. Whitcomb, D.E. MacIntyre, J. Sabry, and R. Gless 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl- urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia Bioorg. Med. Chem. Lett. 21 2011 983 988
3. K. Bernstrom, K. Kayganich, R.C. Murphy, and F.A. Fitzpatrick Incorporation and distribution of epoxyeicosatrienoic acids into cellular phospholipids J. Biol. Chem. 267 1992 3686 3690
4. K.L. Cohen, and S. Harris Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy Arch. Intern. Med. 147 1987 1442 1444 (Pubitemid 17122120)
5. D.L. Eizirik, M.L. Colli, and F. Ortis The role of inflammation in insulitis and beta-cell loss in type 1 diabetes Nat. Rev. Endocrinol. 5 2009 219 226
6. K. Fukuda, G.H. Tesch, F.Y. Yap, J.M. Forbes, R.A. Flavell, R.J. Davis, and D.J. Nikolic-Paterson MKK3 signalling plays an essential role in leukocyte-mediated pancreatic injury in the multiple low-dose streptozotocin model Lab. Invest. 88 2008 398 407 (Pubitemid 351432770)
7. M. Gore, E. Dukes, D.J. Rowbotham, K.S. Tai, and D. Leslie Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings Eur. J. Pain 11 2007 652 664 (Pubitemid 46818059)
8. S.H. Hwang, H.J. Tsai, J.Y. Liu, C. Morisseau, and B.D. Hammock Orally bioavailable potent soluble epoxide hydrolase inhibitors J. Med. Chem. 50 2007 3825 3840 (Pubitemid 47292046)
9. S.H. Hwang, K.M. Wagner, C. Morisseau, J.Y. Liu, H. Dong, A.T. Wecksler, and B.D. Hammock Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase J Med Chem 54 2011 3037 3050
10. J.D. Imig Epoxides and soluble epoxide hydrolase in cardiovascular physiology Physiol. Rev. 92 2012 101 130
11. J.D. Imig, and B.D. Hammock Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases Nat. Rev. Drug Discov. 8 2009 794 805
12. J.D. Imig, X. Zhao, J.H. Capdevila, C. Morisseau, and B.D. Hammock Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension Hypertension 39 2002 690 694 (Pubitemid 34165207)
13. B. Inceoglu, S.L. Jinks, K.R. Schmelzer, T. Waite, I.H. Kim, and B.D. Hammock Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain Life Sci. 79 2006 2311 2319 (Pubitemid 44666069)
14. B. Inceoglu, S.L. Jinks, A. Ulu, C.M. Hegedus, K. Georgi, K.R. Schmelzer, K. Wagner, P.D. Jones, C. Morisseau, and B.D. Hammock Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways Proc. Natl. Acad. Sci. USA 105 2008 18901 18906
15. B. Inceoglu, K. Wagner, N.H. Schebb, C. Morisseau, S.L. Jinks, A. Ulu, C. Hegedus, T. Rose, R. Brosnan, and B.D. Hammock Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP Proc. Nat. Acad. Sci. USA 108 2011 5093 5097
16. N. Inoue, S. Ito, K. Tajima, M. Nogawa, Y. Takahashi, T. Sasagawa, A. Nakamura, and T. Kyoi Etodolac attenuates mechanical allodynia in a mouse model of neuropathic pain J. Pharmacol. Sci. 109 2009 600 605
17. P.D. Jones, H.J. Tsai, Z.N. Do, C. Morisseau, and B.D. Hammock Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase Bioorg. Med. Chem. Lett. 16 2006 5212 5216 (Pubitemid 44247687)
18. S.A. Kanaan, N.E. Saade, J.J. Haddad, A.M. Abdelnoor, S.F. Atweh, S.J. Jabbur, and B. Safieh-Garabedian Endotoxin-induced local inflammation and hyperalgesia in rats and mice: a new model for inflammatory pain Pain 66 1996 373 379 (Pubitemid 26284008)
19. J.Y. Liu, N. Li, J. Yang, H. Qiu, D. Ai, N. Chiamvimonvat, Y. Zhu, and B.D. Hammock Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events Proc. Nat. Acad. Sci. USA 107 2010 17017 17022
20. J.Y. Liu, H.J. Tsai, S.H. Hwang, P.D. Jones, C. Morisseau, and B.D. Hammock Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation Br. J. Pharmacol. 156 2009 284 296
21. C. Morisseau, M.H. Goodrow, D. Dowdy, J. Zheng, J.F. Greene, J.R. Sanborn, and B.D. Hammock Potent urea and carbamate inhibitors of soluble epoxide hydrolases Proc. Natl. Acad. Sci. USA 96 1999 8849 8854 (Pubitemid 29374671)
22. C. Morisseau, B. Inceoglu, K. Schmelzer, H.J. Tsai, S.L. Jinks, C.M. Hegedus, and B.D. Hammock Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids J. Lipid Res. 51 2010 3481 3490
23. C. Morisseau, J.W. Newman, H.J. Tsai, P.A. Baecker, and B.D. Hammock Peptidyl-urea based inhibitors of soluble epoxide hydrolases Bioorg. Med. Chem. Lett. 16 2006 5439 5444 (Pubitemid 44332212)
24. K. Nithipatikom, J.M. Moore, M.A. Isbell, J.R. Falck, and G.J. Gross Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury Am. J. Physiol. Heart. Circ. Physiol. 291 2006 H537 542
25. K.R. Schmelzer, B. Inceoglu, L. Kubala, I.H. Kim, S.L. Jinks, J.P. Eiserich, and B.D. Hammock Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors Proc. Natl. Acad. Sci. USA 103 2006 13646 13651 (Pubitemid 44413961)
26. K.R. Schmelzer, L. Kubala, J.W. Newman, I.H. Kim, J.P. Eiserich, and B.D. Hammock Soluble epoxide hydrolase is a therapeutic target for acute inflammation Proc. Natl. Acad. Sci. USA 102 2005 9772 9777 (Pubitemid 40993644)
27. H.C. Shen Soluble epoxide hydrolase inhibitors: a patent review Expert Opin. Ther. Pat. 20 2010 941 956
28. H.C. Shen, and B.D. Hammock Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications J. Med. Chem 2012
29. A.A. Spector Arachidonic acid cytochrome P450 epoxygenase pathway J. Lipid Res. 50 2009 S52 S56 Suppl
30. A.A. Spector, X. Fang, G.D. Snyder, and N.L. Weintraub Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function Prog. Lipid. Res. 43 2004 55 90 (Pubitemid 37433867)
31. A.A. Spector, and A.W. Norris Action of epoxyeicosatrienoic acids on cellular function Am. J. Physiol. Cell Physiol. 292 2007 C996 1012
32. M. Tomita-Yamaguchi, J.F. Babich, R.C. Baker, and T.J. Santoro Incorporation, distribution, and turnover of arachidonic acid within membrane phospholipids of B220+ T cells from autoimmune-prone MRL-lpr/lpr mice J. Exp. Med. 171 1990 787 800 (Pubitemid 20088982)
33. S. Trelle, S. Reichenbach, S. Wandel, P. Hildebrand, B. Tschannen, P.M. Villiger, M. Egger, and P. Juni Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis BMJ 342 2011 c7086
34. H.J. Tsai, S.H. Hwang, C. Morisseau, J. Yang, P.D. Jones, T. Kasagami, I.H. Kim, and B.D. Hammock Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs Eur. J. Pharm. Sci. 40 2010 222 238
35. A. Ulu, S. Appt, C. Morisseau, S. Hwang, P. Jones, T. Rose, H. Dong, J. Lango, J. Yang, H. Tsai, C. Miyabe, C. Fortenbach, M. Adams, and B. Hammock Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys Br. J. Pharmacol 2011
36. N.M. Wolf, C. Morisseau, P.D. Jones, B. Hock, and B.D. Hammock Development of a high-throughput screen for soluble epoxide hydrolase inhibition Anal. Biochem. 355 2006 71 80 (Pubitemid 44041405)
37. J. Yang, K. Schmelzer, K. Georgi, and B.D. Hammock Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry Anal. Chem. 81 2009 8085 8093
38. W. Zhang, A.L. Yang, J. Liao, H. Li, H. Dong, Y.T. Chung, H. Bai, K.A. Matkowskyj, B.D. Hammock, and G.Y. Yang Soluble Epoxide Hydrolase Gene Deficiency or Inhibition Attenuates Chronic Active Inflammatory Bowel Disease in IL-10(-/-) Mice Dig. Dis. Sci. 57 2012 2580 2591